

The expanding and evolving NSCLC immuno-therapy universe

Number of trials: ● PD(L)1 monotherapy ● PD(L)1 + IO ● PD(L)1 + chemotherapy ● PD(L)1 + other (non-IO/chemotherapy)

Year of trial start:

2012

2013

2014

2015

2016

2017

2018

2019

NSCLC trials with a PD(L)1 mAB

3%

6%

13%

29%

33%

54%

46%

52%

atezolizumab

2

2

4

6

8

4

4

1

2

2

2

3

3

4

3

6

6

6

6

1

1

2

5

10

6

durvalumab

1

5

3

4

6

4

10

1

3

3

2

7

8

1

2

1

2

2

6

3

3

4

3

3

5

8

nivolumab

3

2

4

6

5

12

7

5

2

4

9

20

18

6

2

4

4

11

6

6

3

7

14

13

9

9

pembrolizumab

3

4

7

13

13

7

7

3

1

4

3

15

12

13

2

2

5

9

13

11

1

2

10

8

16

21

20

All other PD(L)1-targeting mABs

3

3

10

18

21

2

1

5

12

4

5

11

20

8

15

17